Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
about
Rapid diagnostic tests for bacterial meningitis applicable in sub-Saharan AfricaPopulation and Functional Genomics of Neisseria Revealed with Gene-by-Gene ApproachesMeningococcal VaccinationsEnter B and W: two new meningococcal vaccine programmes launchedCommunication Challenges During the Development and Introduction of a New Meningococcal Vaccine in AfricaIntroduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014Maternal immunizationAmbiguous Capture: Collaborative Capitalism and the Meningitis Vaccine ProjectEpidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccinationEmergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.After 2015: infectious diseases in a new era of health and development.Metabolic shift in the emergence of hyperinvasive pandemic meningococcal lineagesPhase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage.The contribution of vaccination to global health: past, present and future.Hierarchical genomic analysis of carried and invasive serogroup A Neisseria meningitidis during the 2011 epidemic in Chad.An epidemiological review of changes in meningococcal biology during the last 100 yearsEmergence of a new epidemic Neisseria meningitidis serogroup A Clone in the African meningitis belt: high-resolution picture of genomic changes that mediate immune evasion.Methods of rapid diagnosis for the etiology of meningitis in adultsPersistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013.Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-14Genotypic analysis of meningococcal factor h-binding protein from non-culture clinical specimens.A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.Shifts in the Antibiotic Susceptibility, Serogroups, and Clonal Complexes of Neisseria meningitidis in Shanghai, China: A Time Trend Analysis of the Pre-Quinolone and Quinolone Eras.Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.Response Strategies against Meningitis Epidemics after Elimination of Serogroup A Meningococci, NigerClimate Regimes, El Niño-Southern Oscillation, and Meningococcal Meningitis EpidemicsThe Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.Prevalence and epidemiology of meningococcal carriage in Southern Ethiopia prior to implementation of MenAfriVac, a conjugate vaccineSpeeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market AuthorizationA Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan AfricaActive Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in MaliPublic Health Impact After the Introduction of PsA-TT: The First 4 YearsModeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis BeltHigher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in MaliAntibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina FasoMeningococcal Meningitis Surveillance in the African Meningitis Belt, 2004-2013.Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
P2860
Q24186676-D0AA8019-4830-4A4A-8006-1E0BFBB2AB0DQ26751426-A7D8FB15-0107-43FF-B9F8-FFD0790465F5Q26752993-1DF24D0E-3F8D-4A38-A9A1-11D61167315AQ26775667-98204A4D-5CE7-4210-92CC-D9632350FB6DQ26778266-5911A802-CB4A-4E96-A6B4-C3BC6CE7F9F8Q26778267-612B5D16-521F-4CE6-AE09-20C40C73BF40Q26853746-D9C03F53-6F02-42E9-95A4-8187BEC97171Q28598111-B7F356FD-D228-4B1B-BEA0-3933B83B6DD2Q28659784-C61A7AEB-D449-44A3-B30D-87E3F02C481AQ30239049-1EE19307-7040-4603-8B18-3A8DC6984EE6Q30391463-EF0D01A3-408A-4315-ACF0-1518C1C3AA62Q30397794-1D686025-F24B-4A07-8E6D-0D195952C6ACQ33603065-E3BCDBDC-636B-4BA8-AD6D-236BBB5B6D5BQ33624593-CFEBAE3E-D6CA-4085-83A9-7FF61AD08842Q33717336-15EB5AFC-5FDD-41BD-A17A-CCF24BA76642Q33850814-74F45FC2-5997-4B42-8653-46A2CACFA12DQ34420160-009BF8E7-6A63-4603-A407-51BD27F8E9E7Q34554521-50B7EB93-4F00-464C-AB1E-C9829A29D89CQ34707962-E5EE9177-5921-4A05-81CD-AA0A21456753Q34844225-2158C545-2FD0-4A68-914E-0CCBDBCDDA61Q35064842-10E821B6-5CE2-48CA-808C-254E8D579312Q35108361-C4881045-6B50-4091-8501-4097E28622B4Q35181636-C91C3C93-96B4-4A50-A807-36A948DC9D53Q35658399-1F9D3960-5D3D-47D9-9EFF-8BA689480909Q35887131-7461F4DB-AB25-452E-8F98-6E37768A7C0AQ35897046-FF270725-64CB-4A20-8C2D-EC8932A2EF6FQ35901833-C3195CED-EF09-4658-A266-5B9BE6A51E41Q36078783-9E525CA7-E4FE-4096-A901-F26A72F19FABQ36183088-0EE8B81A-CEEF-4B86-85EE-5F286049655FQ36194240-659369E1-6645-45C9-B62C-D6F261BE364FQ36264995-D744A3B9-3F94-4FE2-A5D2-11D6E4C3C25DQ36265001-ECE88B24-453E-4157-8C6A-49B92E416F54Q36265006-DA2C00FF-E561-4AF2-9FA5-36AAA8AC8D02Q36265017-996CB041-E0E9-4249-A57D-93DD974E04A9Q36265027-DA03A914-0C6F-4723-9D26-5559A1CC98A5Q36265032-44EE16B6-A01E-42B6-9AB2-0121FFF6BD92Q36265037-4CC3CDC5-8D27-4268-82C7-AD9701FE6AB7Q36265054-39F2C40C-4315-43B6-BF47-92B1F4479379Q36265065-D66F8028-A485-4E6C-B971-515C161C8094Q36265080-A52C7ECE-DE6C-4227-9CD7-907156294F76
P2860
Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Effect of a serogroup A mening ...... a community study [corrected].
@ast
Effect of a serogroup A mening ...... a community study [corrected].
@en
type
label
Effect of a serogroup A mening ...... a community study [corrected].
@ast
Effect of a serogroup A mening ...... a community study [corrected].
@en
prefLabel
Effect of a serogroup A mening ...... a community study [corrected].
@ast
Effect of a serogroup A mening ...... a community study [corrected].
@en
P2093
P2860
P50
P1433
P1476
Effect of a serogroup A mening ...... a community study [corrected].
@en
P2093
B Kodbesse
B M Greenwood
D A Caugant
D M Daugla
E R Watkins
P2860
P356
10.1016/S0140-6736(13)61612-8
P407
P577
2013-09-12T00:00:00Z